Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$190.67
-0.9%
$184.21
$163.52
$218.66
$336.80B0.56.25 million shs4.97 million shs
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$135.41
-0.8%
$131.50
$99.71
$141.23
$235.96B0.736.11 million shs3.93 million shs
Cerevel Therapeutics Holdings, Inc. stock logo
CERE
Cerevel Therapeutics
$44.96
$43.67
$19.59
$44.99
$8.19B1.41.71 million shsN/A
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$31.23
$31.23
$3.61
$31.25
$8.32B1.188.78 million shs40 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
0.00%+0.41%+5.04%-10.02%+14.80%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.00%+1.35%+1.51%+6.61%+29.75%
Cerevel Therapeutics Holdings, Inc. stock logo
CERE
Cerevel Therapeutics
0.00%0.00%0.00%0.00%+9.52%
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.9024 of 5 stars
3.45.03.33.93.02.51.3
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.932 of 5 stars
2.45.04.24.52.82.52.5
Cerevel Therapeutics Holdings, Inc. stock logo
CERE
Cerevel Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.81
Moderate Buy$211.2910.81% Upside
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.84
Moderate Buy$142.595.30% Upside
Cerevel Therapeutics Holdings, Inc. stock logo
CERE
Cerevel Therapeutics
0.00
N/AN/AN/A
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ABBV, CERE, ABT, and IMGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold$205.00
6/9/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold$204.00
5/14/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$210.00 ➝ $205.00
5/8/2025
AbbVie Inc. stock logo
ABBV
AbbVie
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
4/29/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$214.00 ➝ $216.00
4/28/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$204.00 ➝ $205.00
4/28/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$241.00 ➝ $250.00
4/22/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$210.00
4/17/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$214.00 ➝ $214.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$133.00 ➝ $145.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$132.00 ➝ $142.00
(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$57.37B5.87$14.09 per share13.53$1.90 per share100.35
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$42.34B5.56$5.83 per share23.22$22.36 per share6.06
Cerevel Therapeutics Holdings, Inc. stock logo
CERE
Cerevel Therapeutics
N/AN/AN/AN/A$3.71 per shareN/A
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$287.61M28.91N/AN/A$0.71 per share43.99
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.28B$2.3579.4513.641.627.59%296.28%12.65%7/24/2025 (Estimated)
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$13.40B$7.7117.7023.632.5231.95%20.74%11.19%7/17/2025 (Estimated)
Cerevel Therapeutics Holdings, Inc. stock logo
CERE
Cerevel Therapeutics
-$432.84M-$2.73N/AN/AN/AN/A-98.94%-45.07%N/A
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
-$222.93M-$0.31N/A84.41N/A-25.56%-22.11%-13.53%N/A

Latest ABBV, CERE, ABT, and IMGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/25/2025Q1 2025
AbbVie Inc. stock logo
ABBV
AbbVie
$2.40$2.46+$0.06$0.72$12.91 billion$13.34 billion
4/16/2025Q1 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.07$1.09+$0.02$0.76$10.38 billion$10.36 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.563.44%N/A279.15%53 Years
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.361.74%N/A30.61%54 Years
Cerevel Therapeutics Holdings, Inc. stock logo
CERE
Cerevel Therapeutics
N/AN/AN/AN/AN/A
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
N/AN/AN/AN/AN/A

Latest ABBV, CERE, ABT, and IMGN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/13/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.591.73%7/15/20258/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
17.94
0.66
0.55
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.32
1.60
1.14
Cerevel Therapeutics Holdings, Inc. stock logo
CERE
Cerevel Therapeutics
0.60
10.22
10.22
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.13
5.70
5.65

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
Cerevel Therapeutics Holdings, Inc. stock logo
CERE
Cerevel Therapeutics
87.73%
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
90.50%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.25%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.46%
Cerevel Therapeutics Holdings, Inc. stock logo
CERE
Cerevel Therapeutics
5.10%
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
5.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.77 billion1.76 billionOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
115,0001.74 billion1.73 billionOptionable
Cerevel Therapeutics Holdings, Inc. stock logo
CERE
Cerevel Therapeutics
300182.20 million172.90 millionOptionable
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
277266.26 million252.76 millionOptionable

Recent News About These Companies

Federal Circuit Affirms ImmunoGen Patent Obviousness
Pivekimab sunirine by ImmunoGen for Blood Cancer: Likelihood of Approval
AbbVie bags EU nod for key drug from ImmunoGen takeover
Artisan International Small-Mid Instl
Artisan International Small-Mid Advisor
Lilly revives ImmunoGen ADC pact with new $1.7bn deal
In Oncology, Antibody-Drug Conjugates Are a Hot Ticket
Polaris Global Equity Composite Q1 2024 Commentary
3 Potential Biopharma Buyout Targets

New MarketBeat Followers Over Time

Media Sentiment Over Time

AbbVie stock logo

AbbVie NYSE:ABBV

$190.67 -1.75 (-0.91%)
Closing price 06/13/2025 03:59 PM Eastern
Extended Trading
$190.74 +0.07 (+0.04%)
As of 06/13/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$135.41 -1.04 (-0.76%)
Closing price 06/13/2025 03:59 PM Eastern
Extended Trading
$136.52 +1.12 (+0.82%)
As of 06/13/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Cerevel Therapeutics stock logo

Cerevel Therapeutics NASDAQ:CERE

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

ImmunoGen stock logo

ImmunoGen NASDAQ:IMGN

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.